Vertex Pharmaceuticals (VRTX) stock in focus as the company updates data from a Phase 1/2/3 trial for its experimental type 1 diabetes drug zimislecel. Read more here.

Vertex Pharmaceuticals has shared data from the Phase I/II segment of the Phase I/II/III FORWARD-101 trial, evaluating the stem cell-derived, fully differentiated islet cell therapy, zimislecel ...

Vertex Pharmaceuticals (NASDAQ: VRTX), a prominent player in the biotechnology industry with a market capitalization of $117 billion, is navigating a pivotal phase in its growth strategy. As the ...

Vertex Pharmaceuticals Presents “Unprecedented” Data for T1D Cell Therapy Zimislecel, Shows Durable Benefit Published on June 24, 2025 at 12:45 pm by Maham Fatima in News ...

Vertex Pharmaceuticals Incorporated today announced simultaneous presentation and publication of updated data from the Phase 1/ 2 portion of the Phase 1/ 2/ 3 FORWARD-101 clinical trial of ...

Vertex's focus for now is on being less of “a one-franchise organisation” and diversifying its portfolio. The company is investigating new medicines for serious diseases with key unmet needs.

If you've been to Twelve Oaks Mall here in Novi recently, you've probably seen the long lines forming in front of a Pop Mart machine. But what are people waiting for?

Orphan drugs for cystic fibrosis and the hereditary rare disease hATTR are on course for European approval after winning the backing of a key regulatory advisory committee. The CHMP’s ...